Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ninlaro Filed in Japan for Post-Transplant Maintenance: Takeda
Takeda Pharmaceutical said on April 25 that it has filed an application seeking a new indication for its multiple myeloma (MM) drug Ninlaro (ixazomib) as a post-autologous stem cell transplant (ASCT) maintenance therapy. Ninlaro hit the Japan market in May…
To read the full story
Related Article
- Takeda Drops US Filing for Ninlaro Label Expansion, Plans Resubmission with OS Data
February 4, 2019
- Ninlaro Shows 39% Improvement in PFS in Post-Transplant Multiple Myeloma Patients: Takeda
December 4, 2018
- Ninlaro Hits Primary Endpoint in Post-Transplant Multiple Myeloma: Takeda
July 13, 2018
- Ninlaro Makes Japan Debut, Mundesine Now Also Available
May 25, 2017
BUSINESS
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…